|Podcasts|December 17, 2021
Diversity and Disruption in Clinical Research
Author(s)Nicholas Saraceno, Editor, Michael Christel
Capital infusion, Nasdaq debut ignite ‘agile’ approach to attracting patients without bounds
Advertisement
David Coman, CEO of Science 37, a decentralized clinical trials platform company, discusses his organization’s recent public debut via the SPAC route, how that’s powering its mission to enable universal and diverse access to clinical research, and the potential of “agile clinical trial” designs in disrupting the future drug development landscape for the better.
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Samsung Biologics Enters US Manufacturing Market with $280M GSK Site Acquisition
2
Pharma Pulse: TrumpRx Gains Nine New Pharma Partners; DHL Expands LAX Cold Chain Hub
3
Pharma Pulse: US Manufacturing Expansion, Oncology Partnerships, and Workplace Health
4
Trade & Channel Strategies 2025: Waiting, Watching, and Reshoring
5